Skip to main content
Top
Published in: Medical Oncology 3/2010

01-09-2010 | Original Paper

Aberrant methylation profile of 14-3-3 sigma and its reduced transcription/expression levels in Chinese sporadic female breast carcinogenesis

Authors: Jie Luo, Jing Feng, Jun Lu, Yuping Wang, Xuanbin Tang, Fei Xie, Wenbin Li

Published in: Medical Oncology | Issue 3/2010

Login to get access

Abstract

To study the relation of 14-3-3 sigma gene promoter hypermethylation and its transcription expression levels in sporadic breast carcinogenesis. Methylation of 14-3-3 sigma gene was detected by sensitive MSP assay in carcinous, non-cancerous, and normal tissue, and its mRNA was also detected by real time PCR based on SYBR Green 1 as well, and protein was detected by west blotting assay. The methylation frequencies of 14-3-3 sigma were 90% in 68 cases of sporadic breast cancer patients. Methylation was presented in portions (2/13, 18%) of hyperplastic samples, and no hypermethylation was presented in normal tissue. The methylation change of 14-3-3 sigma gene was markedly related with various types, grades, and lymph node metastases (P < 0.05), and no significant differences in methylation frequencies were seen between premenopause and postmenopause (P > 0.05). The methylation of 14-3-3 sigma shows reverse relation with its mRNA transcription and expression level (P < 0.05). Only was lymph node metastases strongly associated with poor outcome (P = 0.02). Whether 14-3-3 sigma promoter methylation or not did not affect the 5 years survival rate of sporadic breast cancer patients (P > 0.05). Epigenetics alterations of the 14-3-3 sigma can contribute to reducing or losing expression of 14-3-3 sigma protein, which play an important role in the development of sporadic breast carcinomas and involved in various types, grades, and lymph node metastases. Otherwise, node metastases of breast carcinogenesis patients are strongly associated with poor outcome.
Literature
1.
go back to reference Couch FJ, Weber BL. Breast cancer. In: Scriver CR, Beaudet AL, Sly WS, editors. The metabolic and molecular basis of human disease. New York: McGraw-Hill; 2001. p. 999–1031. Couch FJ, Weber BL. Breast cancer. In: Scriver CR, Beaudet AL, Sly WS, editors. The metabolic and molecular basis of human disease. New York: McGraw-Hill; 2001. p. 999–1031.
2.
go back to reference Leitch AM. Breast cancer screening: success amid conflict. Surg Oncol Clin N Am. 1999;8:657–72.PubMed Leitch AM. Breast cancer screening: success amid conflict. Surg Oncol Clin N Am. 1999;8:657–72.PubMed
3.
go back to reference Tomoshige K, Alexander G, Antonio V, et al. Vpr protein of human immunodeficiency virus type 1 binds to 14–3-3 proteins and facilitates complex formation with Cdc25C: implications for cell cycle arrest. J Biol Chem. 2000;275:23106–12.CrossRef Tomoshige K, Alexander G, Antonio V, et al. Vpr protein of human immunodeficiency virus type 1 binds to 14–3-3 proteins and facilitates complex formation with Cdc25C: implications for cell cycle arrest. J Biol Chem. 2000;275:23106–12.CrossRef
4.
go back to reference Hermeking H, Lengauer C, Polyak K, et al. 14–3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 1997;1(1):3–11.CrossRefPubMed Hermeking H, Lengauer C, Polyak K, et al. 14–3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 1997;1(1):3–11.CrossRefPubMed
5.
go back to reference Chan TA, Hermeking H, Lengauer C, et al. 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 1999;401(6753):535–7.CrossRef Chan TA, Hermeking H, Lengauer C, et al. 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 1999;401(6753):535–7.CrossRef
6.
7.
go back to reference Sambrook J, Russell DW. Molecular cloning. A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001. Sambrook J, Russell DW. Molecular cloning. A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001.
8.
go back to reference Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acid Sci USA. 1996;58:9821–6.CrossRef Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acid Sci USA. 1996;58:9821–6.CrossRef
9.
go back to reference Feng J, Zhang JC, Tao JS, et al. Hypermethylation detection of BRCA1 gene promoter in plasm of sporadic breast cancer patients. China Oncol. 2005;25:442–5. Feng J, Zhang JC, Tao JS, et al. Hypermethylation detection of BRCA1 gene promoter in plasm of sporadic breast cancer patients. China Oncol. 2005;25:442–5.
10.
go back to reference Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. PNAS. 2000;97:6049–54.CrossRefPubMed Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. PNAS. 2000;97:6049–54.CrossRefPubMed
11.
go back to reference Al-Mulla F, Abdulrahman M, Varadharaj G. BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry. J Histochem Cytochem. 2005;53(5):621–9.CrossRefPubMed Al-Mulla F, Abdulrahman M, Varadharaj G. BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry. J Histochem Cytochem. 2005;53(5):621–9.CrossRefPubMed
12.
go back to reference Huiling Y, Yu-Ye W, Ruiying Z, et al. DNA damage-induced protein 14-3-3 sigma inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer. Cancer Res. 2006;66:3097–105. Huiling Y, Yu-Ye W, Ruiying Z, et al. DNA damage-induced protein 14-3-3 sigma inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer. Cancer Res. 2006;66:3097–105.
13.
go back to reference Henrique R, Carmen J, Mohammad OH, et al. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. DNA Cell Biol. 2005;24:264–9.CrossRefPubMed Henrique R, Carmen J, Mohammad OH, et al. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. DNA Cell Biol. 2005;24:264–9.CrossRefPubMed
14.
go back to reference Umbricht CB, Evron E, Gabrielson E, et al. Hypermethylation of 14-3-3 s (stratifin) is an early event in breast cancer. Oncogene. 2001;20:3348–53.CrossRefPubMed Umbricht CB, Evron E, Gabrielson E, et al. Hypermethylation of 14-3-3 s (stratifin) is an early event in breast cancer. Oncogene. 2001;20:3348–53.CrossRefPubMed
15.
go back to reference Kishor B, Abdul KS, Hussain A, et al. The tumor suppressor gene 14-3-3 sigma is commonly methylated in normal and malignant lymphoid cells. Cancer Epidemiol Biomarkers Prev. 2003;12:165–9. Kishor B, Abdul KS, Hussain A, et al. The tumor suppressor gene 14-3-3 sigma is commonly methylated in normal and malignant lymphoid cells. Cancer Epidemiol Biomarkers Prev. 2003;12:165–9.
16.
go back to reference Dmitri L, Heiko H. The role of epigenetic inactivation of 14-3-3 sigma in human cancer. Cell Res. 2005;15:237–46.CrossRef Dmitri L, Heiko H. The role of epigenetic inactivation of 14-3-3 sigma in human cancer. Cell Res. 2005;15:237–46.CrossRef
17.
go back to reference Chan TA, Hermeking H, Langauer C, et al. 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 1999;401:616–20.CrossRefPubMed Chan TA, Hermeking H, Langauer C, et al. 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 1999;401:616–20.CrossRefPubMed
18.
go back to reference Morrison TB, Weis JJ, Wittwer CT. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques. 1998;24:954–62.PubMed Morrison TB, Weis JJ, Wittwer CT. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques. 1998;24:954–62.PubMed
19.
go back to reference Moreira JM, Ohlsson G, Rank FE, Celis JE. Down-regulation of the tumor suppressor protein 14-3-3 is a sporadic event in cancer of the breast. Mol Cell Proteomics. 2005;4:555–69.CrossRefPubMed Moreira JM, Ohlsson G, Rank FE, Celis JE. Down-regulation of the tumor suppressor protein 14-3-3 is a sporadic event in cancer of the breast. Mol Cell Proteomics. 2005;4:555–69.CrossRefPubMed
20.
go back to reference Dong ES, Jang SJ, Kim JS, et al. Expression of the 14-3-3 sigma protein and methylation status of the 14-3-3 sigma gene in biliary neoplasms. Korean J Pathol. 2006;40:9–16. Dong ES, Jang SJ, Kim JS, et al. Expression of the 14-3-3 sigma protein and methylation status of the 14-3-3 sigma gene in biliary neoplasms. Korean J Pathol. 2006;40:9–16.
21.
go back to reference Ulrich L, Florian L, Henning F, et al. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol. 2002;160:605–12. Ulrich L, Florian L, Henning F, et al. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol. 2002;160:605–12.
22.
go back to reference Ramirez JL, Rafael R, Taron M, et al. 14-3-3 sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non–small-cell lung cancer patients predicts survival: the spanish lung cancer group. J Clin Oncol. 2005;23:9105–12.CrossRefPubMed Ramirez JL, Rafael R, Taron M, et al. 14-3-3 sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non–small-cell lung cancer patients predicts survival: the spanish lung cancer group. J Clin Oncol. 2005;23:9105–12.CrossRefPubMed
23.
go back to reference Norikazu I, Hiroyuki Y, Shigeru S, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene. 2000;19:5298–302.CrossRef Norikazu I, Hiroyuki Y, Shigeru S, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene. 2000;19:5298–302.CrossRef
Metadata
Title
Aberrant methylation profile of 14-3-3 sigma and its reduced transcription/expression levels in Chinese sporadic female breast carcinogenesis
Authors
Jie Luo
Jing Feng
Jun Lu
Yuping Wang
Xuanbin Tang
Fei Xie
Wenbin Li
Publication date
01-09-2010
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9287-8

Other articles of this Issue 3/2010

Medical Oncology 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.